193 related articles for article (PubMed ID: 26381514)
1. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Winters N; Butler-Laporte G; Menzies D
Eur Respir J; 2015 Nov; 46(5):1461-70. PubMed ID: 26381514
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Yoon HY; Jo KW; Nam GB; Shim TS
Int J Tuberc Lung Dis; 2017 Sep; 21(9):996-1001. PubMed ID: 28826448
[TBL] [Abstract][Full Text] [Related]
3. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.
Dauby N; Muylle I; Mouchet F; Sergysels R; Payen MC
Pediatr Infect Dis J; 2011 Sep; 30(9):812-3. PubMed ID: 21378593
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
[TBL] [Abstract][Full Text] [Related]
5. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
Fox GJ; Benedetti A; Cox H; Koh WJ; Viiklepp P; Ahuja S; Pasvol G; Menzies D;
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049171
[TBL] [Abstract][Full Text] [Related]
6. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Van der Walt M; Lancaster J; Odendaal R; Davis JG; Shean K; Farley J
PLoS One; 2013; 8(4):e58817. PubMed ID: 23573193
[TBL] [Abstract][Full Text] [Related]
7. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Sotgiu G; D'Ambrosio L; Centis R; Tiberi S; Esposito S; Dore S; Spanevello A; Migliori GB
Int J Mol Sci; 2016 Mar; 17(3):373. PubMed ID: 26985890
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.
van der Paardt AF; Wilffert B; Akkerman OW; de Lange WC; van Soolingen D; Sinha B; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2015 Aug; 46(2):444-55. PubMed ID: 26022960
[TBL] [Abstract][Full Text] [Related]
9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
Palmero D; González Montaner P; Cufré M; García A; Vescovo M; Poggi S
Arch Bronconeumol; 2015 Oct; 51(10):e49-52. PubMed ID: 26026689
[TBL] [Abstract][Full Text] [Related]
13. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities.
Lienhardt C; Davies G
Int J Tuberc Lung Dis; 2010 May; 14(5):528-37. PubMed ID: 20392344
[TBL] [Abstract][Full Text] [Related]
14. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
Xu HB; Jiang RH; Li L; Xiao HP
Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
[TBL] [Abstract][Full Text] [Related]
15. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.
Hwang TJ; Wares DF; Jafarov A; Jakubowiak W; Nunn P; Keshavjee S
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1257-66. PubMed ID: 23735593
[TBL] [Abstract][Full Text] [Related]
16. Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
[TBL] [Abstract][Full Text] [Related]
17. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
[TBL] [Abstract][Full Text] [Related]
18. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for multidrug-resistant tuberculosis.
Seung KJ; Becerra MC; Atwood SS; Alcántara F; Bonilla CA; Mitnick CD
Clin Microbiol Infect; 2014 May; 20(5):441-6. PubMed ID: 23991934
[TBL] [Abstract][Full Text] [Related]
20. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.
Chang KC; Yew WW; Tam CM; Leung CC
Antimicrob Agents Chemother; 2013 Sep; 57(9):4097-104. PubMed ID: 23774431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]